Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Inclusion Criteria:

• Age >= 18 years

• Relapsed or refractory:

• Group E only: Relapsed peripheral T-cell lymphoma (PTCL) of the followinghistologies: peripheral T-cell lymphoma-NOS (PTCL-NOS); anaplastic large cell (ALCL), and mycosis fungoides (MF)

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 times upperlimit of normal (ULN) (obtained =< 15 days prior to registration)

• Creatinine =< 2.0 mg/dL (obtained =< 15 days prior to registration)

• Direct bilirubin =< 1.5 x ULN (obtained =< 15 days prior to registration)

• International normalized ratio (INR)/prothrombin time (PT) and activated partialthromboplastin time (aPTT) =< 1.5 x ULN (obtained =< 15 days prior to registration)

• If baseline liver disease, Child Pugh score not exceeding class A (obtained =< 15days prior to registration)

• Negative pregnancy test for persons of child-bearing potential (obtained =< 15 daysprior to registration)

• FOR T-Cell Lymphoma (TCL)/B-Cell Lymphoma (BCL) ONLY: Absolute Neutrophil Count (ANC) >= 1,000/microliter (μL) (obtained =< 14 days prior to registration)

• FOR TCL/BCL ONLY: Platelets >= 100,000/μL (obtained =< 14 days prior toregistration)

• FOR TCL/BCL ONLY: Hemoglobin >= 8.5 g/dl (obtained =< 14 days prior to registration)

• FOR TCL/BCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): musthave at least one lesion that has a single diameter of > 2 cm or tumor cells in theblood > 5 x 10^9/L; NOTE: skin lesions can be used if the area is > 2 cm in at leastone diameter and photographed with a ruler and the images are available in themedical record

• Absence of active central nervous system (CNS) involvement; NOTE: pre-enrollmentlumbar puncture not mandatory

• Ability to provide written informed consent

• Willingness to return to Mayo Clinic for follow-up

• Life expectancy >= 12 weeks

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

• Willing to provide mandatory biological specimens for research purposes

Exclusion Criteria:

• Availability of and patient acceptance of curative therapy

• Uncontrolled infection

• Active tuberculosis or hepatitis, or chronic hepatitis

• Any of the following prior therapies:

• Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =< 2 weeks priorto registration

• Immunotherapy (monoclonal antibodies) =< 4 weeks prior to registration

• Experimental agent in case of Acute Myeloid Leukemia (AML) or TCL within 4half-lives of the last dose of the agent

• New York Heart Association classification III or IV, known symptomatic coronaryartery disease, or symptoms of coronary artery disease on systems review, or knowncardiac arrhythmias [atrial fibrillation or supraventricular tachycardia (SVT)]

• Active CNS disorder or seizure disorder or known CNS disease or neurologicsymptomatology; in case of AML active CNS involvement as detected by lumbar punctureor neuro-imaging (only to be done if clinically indicated)

• Human immunodeficiency virus (HIV) positive test result or other immunodeficiency orimmunosuppression

• Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapyconsidered investigational (used for a non-Food and Drug Administration [FDA]approved indication and in the context of a research investigation);

• NOTE: in TCL, patients may use topical emollients or corticosteroids, aceticacid soaks, etc. to control pruritis and prevent infection; no topicalchemotherapy is allowed (no topical nitrogen mustard)

• Any of the following because this study involves an investigational agent whosegenotoxic, mutagenic and teratogenic effects on the developing fetus and newborn areunknown:

• Pregnant women or women of reproductive ability who are unwilling to useeffective contraception

• Nursing women

• Men who are unwilling to use a condom (even if they have undergone a priorvasectomy) while having intercourse with any woman, while taking the drug andfor 4 weeks after stopping treatment

• ADDITIONAL EXCLUSION CRITERIA FOR GROUP E (COMBINATION WITH IPILIMUMAB ANDCEMIPLIMAB) ONLY:

• Diagnosis of AML

• Diagnosis of Angioimmunoblastic T-cell Lymphoma (AITL)

• Hypersensitivity to ipilimumab or its excipients